Venture Capital

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Promising long-term data and key regulatory wins position Wugen's allogeneic therapy to disrupt the challenging T-cell cancer treatment landscape.

China Automotive Systems' new high-torque motor isn't just a component; it's a strategic play for the future of autonomous trucking and a challenge to incumbents.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?

Pershing Square's latest share repurchase is more than routine; it's a strategic move to close a stubborn valuation gap and signal deep confidence.

A monumental $31.5 billion contract tasks Peraton with replacing the FAA's aging air traffic control system. Can it succeed where others have failed?

A key accelerator selection puts South Korean startup ALL CONEC and its AI-driven dental platform in the spotlight, backed by Oracle's cloud power.

With new funding, Japan's Helical Fusion is racing to build a fusion plant by the 2030s. Can its unique stellarator technology win the clean energy race?

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

A new partnership between Pellera Technologies and the NY Rangers is more than a sponsorship. It's a strategic play on heritage, B2B marketing, and community.

How Winemaker of the Year Jesse Katz blends record-setting sales, historic vineyards, and philanthropy to disrupt the ultra-premium wine market.

A new book on stuttering highlights a growing trend: using storytelling as a powerful, low-tech innovation to foster empathy and address childhood health.

An IT giant's partnership with the NY Rangers is more than ads. It's a masterclass in post-merger branding and a look at the future of B2B marketing.

With AI creating a data center power crisis, one company's safer, greener nickel-zinc batteries are attracting major investment. Here's why it matters.

An award-winning conservation group is turning holiday shopping into a revenue stream for reef restoration. Is this the future of environmental funding?